Optimize RV Selective Site Pacing Clinical Trial

NCT ID: NCT00422669

Last Updated: 2013-01-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

205 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the Optimize RV study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed. The goal of select site pacing is to improve how the heart contracts when paced in the ventricle. By pacing in select sites, it is possible to better copy the natural pattern of contraction of the heart.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Pacing, Artificial Cardiac Pacemaker, Artificial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RV Mid-Septal Pacing

Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart

Group Type ACTIVE_COMPARATOR

Medtronic Dual-Chamber Pacemaker

Intervention Type DEVICE

A Medtronic market-approved dual-chamber implantable pulse generator (IPG)

Medtronic SelectSecure 3830 Lead

Intervention Type DEVICE

Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead

RV Apical Pacing

Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex

Group Type ACTIVE_COMPARATOR

Medtronic Dual-Chamber Pacemaker

Intervention Type DEVICE

A Medtronic market-approved dual-chamber implantable pulse generator (IPG)

Medtronic SelectSecure 3830 Lead

Intervention Type DEVICE

Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medtronic Dual-Chamber Pacemaker

A Medtronic market-approved dual-chamber implantable pulse generator (IPG)

Intervention Type DEVICE

Medtronic SelectSecure 3830 Lead

Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects that are expected to be paced in the right ventricle (RV) greater than 90 percent of the time
* Subjects with an ejection fraction of greater than 40 percent within 3 months prior to enrollment
* Subjects greater than 18 yrs of age
* Subjects that are indicated for a dual chamber pacemaker
* Subjects that will be implanted with a market released dual chamber Medtronic pacemaker and 3830 SelectSecure Lead in the ventricle

Exclusion Criteria

* Subjects indicated for cardiac resynchronization therapy (CRT) device (based on American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines)
* Subjects indicated for an implantable cardiac defibrillator (ICD)
* Subjects with permanent atrial fibrillation (AF)
* Subjects with expected managed ventricular pacing turned on
* Subjects with a previously implanted pacemaker, ICD, or CRT device
* Subjects with an myocardial infarction (MI) within 3 months prior to enrollment
* Subjects that received bypass surgery within 3 months prior to enrollment
* Subjects that had valve replacement within 3 months prior to enrollment
* Subjects where a RV lead cannot be placed, (i.e., complex congenital heart disease
* Subjects with a mechanical right heart valve
* Women who are pregnant or nursing
* Significant co-morbidity preventing study completion
* Terminal conditions with a life expectancy of less than two years
* Participation in another study that would confound the results of this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Optimize RV Team

Role: STUDY_CHAIR

Medtronic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bridgeport, Connecticut, United States

Site Status

Clearwater, Florida, United States

Site Status

Hudson, Florida, United States

Site Status

Des Moines, Iowa, United States

Site Status

Silver Spring, Maryland, United States

Site Status

Takoma Park, Maryland, United States

Site Status

Southfield, Michigan, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

Omaha, Nebraska, United States

Site Status

Cleveland, Ohio, United States

Site Status

Nashville, Tennessee, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Tomball, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Burlington, Vermont, United States

Site Status

Montreal, , Canada

Site Status

Hong Kong, , China

Site Status

Ramat Gan, , Israel

Site Status

Florence, , Italy

Site Status

Rovigo, , Italy

Site Status

Doha, , Qatar

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada China Israel Italy Qatar

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

604

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Optimizing CRT With ECGI
NCT03492788 TERMINATED NA